In the real world, the selection of a therapeutic modality like an antibody or peptide is often driven by a company's existing expertise and technology platform rather than a purely agnostic approach to finding the single best tool for a clinical problem. Organizations default to the tools in their toolbox.

For new technologies to gain adoption in pharma, the central value proposition must be about de-risking decisions. Leaders and regulators often view the technology as a "black box" and are less concerned with its mechanics than with its ability to give them confidence in making safer, more reliable choices.

The pharmaceutical industry's historically high profitability created a lack of urgency for technological innovation beyond basic ERP systems. It wasn't until patent cliffs and messy M&A integrations squeezed margins that companies began seriously investing in modern data platforms and cloud infrastructure to improve efficiency.

To maximize advantages, an in-house lab consciously selected a different NGS testing platform than major external vendors. This strategic choice not only reduced tissue sample requirements but also offered a faster turnaround time due to the underlying technology, creating a distinct competitive advantage beyond mere proximity.

Guardant's co-CEO argues that in complex fields like diagnostics, success hinges more on innovating the business model than the core technology. Superior tech fails if it doesn't align with the unique economic incentives where the user isn't the payer.

The primary barrier to implementing AI for antibody developability isn't the tech, which has been available for over a decade. MIT's Bernhard Trout states the real failure point is a lack of sustained corporate commitment, as key personnel are frequently reassigned to other projects, causing initiatives to stall.

Alternative biomanufacturing platforms succeed not by trying to universally replace the industry-standard CHO cells, but by identifying and dominating specific niches where CHO has weaknesses—such as cost, speed, or intrinsic product quality for certain molecules.

Many MedTech companies mistakenly believe a clinically superior product will automatically win market share. This is false. Market adoption is not automatic; it must be designed as intentionally as the product itself to overcome the powerful inertia of the status quo and make the market mentally ready for change.

In bioprocessing, it is more efficient to design a development process that accommodates the constraints of the manufacturing facility. Forcing a plant to adapt to a rigid process is difficult and costly. This includes making early, scalable choices about materials like chromatography resins to ensure a smooth tech transfer.